A role for mismatch repair in control of DNA ploidy following DNA damage

被引:28
作者
Strathdee, G
Sansom, OJ
Sim, A
Clarke, AR
Brown, R [1 ]
机构
[1] Univ Glasgow, CRC, Beatson Labs, Dept Med Oncol, Glasgow G61 1BD, Lanark, Scotland
[2] Univ Edinburgh, Sch Med, Dept Pathol, CRC Labs, Edinburgh EH8 9AG, Midlothian, Scotland
[3] Univ Wales Coll Cardiff, Cardiff Sch Biosci, Cardiff CF10 3US, S Glam, Wales
关键词
mismatch repair; cell cycle; polyploidy; p53; DNA damage;
D O I
10.1038/sj.onc.1204276
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Many reports have shown a link between mismatch repair (MMR) deficiency and loss of normal cell cycle control, particularly loss of G2 arrest. However almost all of these studies utilized transformed cell lines, and thus the involvement of other genes in this phenotype cannot be excluded. We have examined the effects of cisplatin treatment on primary embryo fibroblasts (MEFs) derived from mice in which the MMR gene Msh2 had been inactivated (Msh2(-/-)). This analysis determined that both primary Msh2(-/-) and wild type (WT) fibroblasts exhibited an essentially identical G2 arrest following cisplatin treatment. Similarly, we observed a cisplatin-induced G2 arrest in immortalized MMR deficient (Mlh1 (/) and Pms2(-/-)) and WT MEFs, p53 deficient primary MEFs (p53(-/-)) exhibited both a clear G2 arrest and an increase in cells with a DNA content of 8N in response to cisplatin, When the Msh2 and p53 defects were combined (p53(-/-)/Msh2(-/-)) the G2 arrest was essentially identical to the p53(-/-) fibroblasts. However, the p53(-/-)/Msh2(-/-) fibroblasts demonstrated a further increase in cells with an 8N DNA content, above that seen in the p53 (/) fibroblasts, These results suggest that loss of MMR on its own is not enough to overcome G2 arrest following exposure to cisplatin but does play a role in preventing polyploidization, or aberrant DNA reduplication, in the absence of functional p53.
引用
收藏
页码:1923 / 1927
页数:5
相关论文
共 29 条
[1]  
Anthoney DA, 1996, CANCER RES, V56, P1374
[2]  
Arzimanoglou II, 1998, CANCER-AM CANCER SOC, V82, P1808, DOI 10.1002/(SICI)1097-0142(19980515)82:10<1808::AID-CNCR2>3.0.CO
[3]  
2-J
[4]   p53 in signaling checkpoint arrest or apoptosis [J].
Bates, S ;
Vousden, KH .
CURRENT OPINION IN GENETICS & DEVELOPMENT, 1996, 6 (01) :12-18
[5]   hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents. [J].
Brown, R ;
Hirst, GL ;
Gallagher, WM ;
McIlwrath, AJ ;
Margison, GP ;
vanderZee, AGJ ;
Anthoney, DA .
ONCOGENE, 1997, 15 (01) :45-52
[6]   INCREASED ACCUMULATION OF P53 PROTEIN IN CISPLATIN-RESISTANT OVARIAN CELL-LINES [J].
BROWN, R ;
CLUGSTON, C ;
BURNS, P ;
EDLIN, A ;
VASEY, P ;
VOJTESEK, B ;
KAYE, SB .
INTERNATIONAL JOURNAL OF CANCER, 1993, 55 (04) :678-684
[7]   Mammalian DNA mismatch repair [J].
Buermeyer, AB ;
Deschênes, SM ;
Baker, SM ;
Liskay, RM .
ANNUAL REVIEW OF GENETICS, 1999, 33 :533-564
[8]   Female embryonic lethality in mice nullizygous for both Msh2 and p53 [J].
Cranston, A ;
Bocker, T ;
Reitmair, A ;
Palazzo, J ;
Wilson, T ;
Mak, T ;
Fishel, R .
NATURE GENETICS, 1997, 17 (01) :114-118
[9]   A P53-DEPENDENT MOUSE SPINDLE CHECKPOINT [J].
CROSS, SM ;
SANCHEZ, CA ;
MORGAN, CA ;
SCHIMKE, MK ;
RAMEL, S ;
IDZERDA, RL ;
RASKIND, WH ;
REID, BJ .
SCIENCE, 1995, 267 (5202) :1353-1356
[10]   DNA damage-induced cell cycle checkpoints and DNA strand break repair in development and tumorigenesis [J].
Dasika, GK ;
Lin, SCJ ;
Zhao, S ;
Sung, P ;
Tomkinson, A ;
Lee, EYHP .
ONCOGENE, 1999, 18 (55) :7883-7899